A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects.

Trial Profile

A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2009

At a glance

  • Drugs Otenabant; Sibutramine
  • Indications Obesity
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Aug 2009 Actual patient number (282) added as reported by ClinicalTrials.gov.
    • 30 Aug 2006 Status change
    • 11 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top